Ionis Pharmaceuticals (IONS) Tops Q4 EPS by 35c, Revenues Beat; Offers FY20 Revenue Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
February 26, 2020 7:01 AM ESTBOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, Interim CEO, will present at the Cowen 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 10:40 a.m. ET.
The above listed date is subject to change. Details on presentation times or changes to presentation dates can be found on the Companys website. Please check... More
